Why ImmunoGen, Inc. Shot Up Today

By Brian Orelli Markets Fool.com

What happened

Continue Reading Below

ImmunoGen (NASDAQ: IMGN) is up 11.7% at 11:52 a.m. EDT after an analyst at Leerink upgraded the biotech to outperform and slapped an $8 price target on the stock.

So what

ImmunoGen has been on a tear over the last few months, up 78% year to date. As we often see with biotechs, investors left ImmunoGen for dead last year without any impending catalysts, and are buying back in now, with the company expected to release data this quarter.

Image source: Getty Images.

The data will come from a phase 1b/2 trial called FORWARD II, which is testing ImmunoGen's lead drug mirvetuximab soravtansine in combination with Avastin, carboplatin, Doxil, or Keytruda. Investors can also expect pooled data from multiple phase 1 trials testing mirvetuximab soravtansine as a monotherapy in patients with ovarian cancer. Some of that data will include patients taking steroid eye drops to manage a side effect of the drug.

Continue Reading Below

All of that data should help investors get a better picture of how ImmunoGen's phase 3 FORWARD Itrial in patients with platinum-resistant ovarian cancer will turn out. Data from the FORWARD I trial is still a few years away from being available, so any boost in confidence should go a long way toward holding up ImmunoGen's valuation until it's clear whether mirvetuximab soravtansine can be approved by regulators.

Now what

It's back to waiting. If management sticks to its timeline of releasing data this quarter, investors will get the data they're looking for in the next 2 1/2 months -- but hopefully, earlier.

10 stocks we like better than ImmunoGen
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and ImmunoGen wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of April 3, 2017

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends ImmunoGen. The Motley Fool has a disclosure policy.